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SUMMARY
Using 49 prostatectomized patients as experimental subjects, we studied the effects of Inclometnacin
and acetylsalicylic acid — accredited prostaglandin synthetase inhibitors — from a urodynamic and clinical
standpoint. Relevant urodynamic data was gathered 1 hr 30 mi after the patients had taken the drugs and
placebo. Clinical results were further scrutinized after 8 days of treatment, at which time a new urodynamic
workup was again performed on some patients. Results were again studied shortly after the end of treat
ment. The effect of the drugs on bladder and urethral structures was borne out by clear-ct!t clinical and
urodynamic changes. After statistically analyzing such changes, we concluded that prostaglandin synthesis
inhibition resulting in the inhibition of prostaglandin action had, at least in part, led to the changes noted.
In the present report we shall discuss the role played by the highly complex mechanisms at work.
RESUMO
O PAPEL DAS PROSTAGLANDINAS NA DINÂMICA DO TRACTO URINÁRIO
INFERIOR DE DOENTES PROSTATECTOMIZADOS: UM ENSAIO COM
INDOMETACINA E ASPIRINA
Usando 59 doentes prostatectomizados como modelo experimental, os AA estudaram os efeitos da in
dometacina e do ácido acetilsalicílico — inibidores acreditados da sintetase prostaglandinica — sob o pon
to de vista urodinâmico e clínico.
Os dados urodinâmicos foram colhidos 1 hora e 30 minutos depois de os doentes terem tomado Placebo
ou os medicamentos e os resultados clínicos depois de 8 dias de tratamento, ao fim dos quais foi feito um
novo estudo urodinâmico em alguns doentes. Os resultados clínicos foram analisados, de novo, pouco tem
po depois determinado o tratamento. O efeito dos medicamentos na bexiga e nas estruturas uretrais foi de
monstrado pelas nítidas alterações clínicas e urodinâmicas. Depois de analisar estatisticamente os resulta
dos, os AA concluem que a inibição da sintetase prostaglandínica e consequente inibição da acção das
prostaglandinas conduziu, pelo menos em parte, às alterações verificadas, cujos mecanismos, altamente
complexos, são discutidos.
INTRODUCTION
Research has already been carried out iii vitro and in
experimental animais in order to determine the effect of
prostaglandins on bladder and urethral stru
ctures.25’12282931’5267 The causes behind possibie synthesis
stimuli182228’29’31’57587074 and activating mechanisms of
bladder and urethral structures have been the subi ect of se
veral papers.11’2536-43’50’52’61”6-78 Only very spotty work has
been done, nevertheless, on human beings in ~j~~.1215~4
Our clinical study and thorough urodynamic research
project, which begun in 1979, had as its aim the better un
derstanding of the role of prostaglandins in normal and pa
thological vesico-sphincteric dynamics. The patients chosen
as the target group of our study had ali undergone open sur
gery for benign hypertrophy of the prostate. Since such pa
tients often display vesico-urethral dysfunctions,1’48183’85-87
and exhibit a posterior urethra simplified and reduced to
the distal sphincters144559’65818286 (Fig. 1), we reasoned that
the study of changes undergone in this area would be easier
to chart.
Changes brought about by the synthesis inhibition of
endogenous prostaglandins and related substances provided
us with the data we needed for our study. To effect the desi
red result, we used two drugs, indomethacin and aspirin,
which despite their total chemical dissimilarity, both inhibit
prostaglandin synthesis.21’75’88 The study of accumulated ex
perimental and clinical data13’19’21’24’62’75’88 provided us with
the dosage of both drugs (sufficient to completely inhibit
the synthesis of prostaglandins and related substances) and
the spacing of administrations.
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59 patients were chosen on the basis of strict clinical, ra
diologicai and laboratorial criteria. When necessary, an
I.V.P. was performed. Retrograde and micturition cystou
rethrograms were done on all patients and an endoscopy
was performed whenever the presence of an organic lesion
was suspected. When confirmed, the patient was excluded.
Also excluded were patients with diabetes, neurological or
psichiatric disorders, persistent organic bladder neck and
urethral obstructions, total sphyncteric incontinence, and
those operated for simuitaneous vesical lesions. The use of
indomethacin and aspirin ied us to rule out patients with
gastroduodenal ulcers as weii. Patients were not allowed to
take any other type of medication starting at least a week
before and during the period of the trial.
A three-month post-operative time lapse was considered
the minimum necessary for the probable eradication of resi
dual infiarnmation and the epithelization of the area opera
ted on. Given our interest in studying the clinical effects of
our therapy we tried to bring together ali patients we could
suffering from functional disorders, that become rarer after
that time period.4
A pre-operative and current ciinicai picture of each case
was formed, using a clinical protocoi that helped us to piace
the patients in two categories: normal (assymptomatic) with
16 cases, and those suffering from a variery of functional
disturbances — 43 cases. The patients were then divided in
to three main groups: placebo group with 12 patients, 8 of
whom later became part of the indomethacin group which
had 47 cases in ali, and 4 of whom later joined the aspirin
group composed of 12 cases.
At the onset ol our trial ail patients underwent a urody
namic work-up listed on Table 1, in which the terrninology
used is shown. A Disa (R) system was used. Urethral pressu
re profiles were not perfomed. International Continence So
ciety4749 recomrnendations, terminology, units and symbois
were used whenever possibie. The procedure foliowed in
each urodynamic work-up and a few details not clearly in
ciuded in International Continence Society reports need to
be described.
With the patient supine, after having passed urine, a 1 2F
poiyethylene urethrai catheter was introduced under local
anesthesia and residual urine was measured. The bladder
was then filied at a continous rate of approximateiy 2 ml s-1
with a room temperature normal saline soiution. In 39 ca
ses, pressures (cm H2 O) were measured, with a suprapubic
5 F poiyethyiene catheter and in the remaining cases with a
6 F polyethylene urethrai catheter. Abdominal pressure was
measured using a rectal iatex baloon catheter. Detrusor
pressures were indirectiy obtained, by subtracting abdomi
nal from intravesical pressures. Maximum abdominal and
detrusor pressures were not measured. Detrusor post
-micturition contraction pressure was obtained as indicated
for the other detrusor pressures.
The slope’s tonus limb and colagen segment, when de
tectabie10’72’6° were mathernaticaiiy analysed (cm H2 O per
100 mi), as prescribed by Merril et a16° and graphically re
presented. The sarne values which were directly measured
on the intravesical pressure curve, were used to caiculate the
compiiance in the muscular and colagen phases of biadder
fiiling and are expressed in ml for cm H2 O.~
To detect possible detrusor instabiiity provocative sti
muli such as coughing, standing and heei jouncing were em
pioyed during this phase.
22
THE ROLE OF PROSTAGLANDINS IN THE LOWER URINARY TRACf
Micturition pressures and flow (ml s-1) were then stu
died and either intermitent (1) or continous (C) patterns of
the flow were noted along with cases of terminal dribble
(D).
Urethral resistance (units) was measured using the for
mula:
The reiationship between pressure (intravesicai and detru
sor, at maximum flow) and maximum flow was analysed
using the guidelines established by Abrams and Torrens,3
Griffiths35 and adopted by the International Continence So
ciety.49 The relationship was then depicted on graphs.
At the end of micturition, residual urine was again mea
sured and figures confirmed by subtracting voided volume
from maximum cystometric capacity.
External sphincter eiectromiography was performed on
ali patients.
The work-up was repeated 1 hr. 30 mm. after the admi
nistration with miik of a piacebo (12 cases), 150 mg of indo
methacin in capsules (47 cases), or 2.000 mg of aspirin in ta
blet form (12 cases). The placebo administered, it may be
added, was identical in appearance to the drug to be taken
by the patient iater on, when participating in the indome
thacin or aspirin groups.
In the next stage, patients with clinical disturbances we
re singled out for 8 days of treatment, sufficient time for re
liable results but not long enough to permit the natural ten
dency of this kind of patients to improve to significantly im
pair the conclusions. A placebo was administered to 12 pa
tients (who between a week and a month later became part
of the other two groups), 50 mg of indomethacin, 3 times
per day at approximate 8-hour mealtime intervais to 32 pa
tients; or 1.000 mg of aspirin, 3 times a day at 8-hour meal
time intervals, to 9 patients. After 8 days were over, a
fourth group was formed with 5 patients from the indome
thacin group. These patients underwent another identical
urodynamic work-up in order to note any further changes
that may have taken place.
Finally, doctors (unaware of what the patients had been
given) analysed ali placebo, aspirin and indomethacin pa
tients with clinical disturbances, after the 8 days were over,
in order to note any changes in symptoms.
Of the 41 patients submitted to therapy for clinical dis
turbances (indomethacmn-32; aspirin-9), we succeeded in
contacting 27 (indomethacin-23; aspirin-4) between 15 and
45 days after the end of therapy, and were thus able to ga
ther more useful information regarding the further evolu
tion of symptoms in each case.
Clinical changes and urodynamic alterations were com
pared with the results gathered from studying the placebo
group.
The subjective nature of symptoms, the variability of
their frequency in each group, the sparceness of certain
symptoms as a whole, and the need to qualify some results
by grading them, thus avoiding the ali or nothing approach,
led us to prefer the presentation of clinical results without a
statistical analysis. Thus, changes noted are expressed in
terms of percentages.
The uniformity of ali 4 groups at the start was checked
statistically using the Student’s t test, based on urodynamic
figures, obtained before medication had been given.
Urodynamic alterations underwent a statistical paired t
test analysis since the patients functioned as their own con
trol. The graphs presented, show the means and standard
error of the means.
The following symbols were used on the graphs, depen




The Fischer and Yates table23 was ijsed.
It is important to stress that both clinical and urodyna
mic results were analysed within each group through com
parison of the results obtained before and after the adminis
tration of the drugs or placebo. We did not attempt to com
pare the groups; the placebo patients were used to give us an
TABLE 1. Urodynamic terminology.
First desire to void FS Continuous flow QC
Maximum cystometric capacity Cap, max lntermittent 110w QI
Effective cystometric capacity.. . Cap, ef Terminal dribbling QD
Instability 1 Flow time Qt
Instability — detrusor pressure . . I(Pdet) Time to maximum 110w. . Qtmax
Slope: Maximum flow Qmax
Smooth muscle segment Sm Voided volume Vv
Smooth colagen segment Sc Average flow rate Qmed
Compliance: Voiding time Mt
Smooth muscle phase Cm Residual urine Res
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idea of the natural evolution of the situation independent of
the action of drugs and under the influence of the instru
mentation for the urodynamic study.
RESULTS
Our findings showed that patients subjected to the in
fluence of indomethacin and aspirin experienced a clinicial
improvement in symptoms that was not apparent in the pia
cebo group (Table 2). The fact that there was larger number
of subjects in the indomethacin group than in the aspirin
group undoubtedly conditioned results obtained. Although
= 100%
a)
Numberof 4 16.7% 4 68.8% 4 44.4%
micturitions par = 83.3% = 31.2% 55.6%
night
Falte desire (n = 2) (n = 9)
tovoid 4 55.6%
= 100% = 11.1%
- 33.3%
(n = 6) (a = 15) (n 3)
4 16.7% 4 66.7% 4 66.7%
tirgency = 83.3% = 6.7% = 33.3%
— 26.6%
Stress (a = 1) (n = 1)
incontinence 8 100% t 100%
Urge (n = 2)
iucontinence — 100%
(a = 5) (a = 13) (n = 4)
Terminal 415.4% 475%
dribb)ing = 100%
— 84.6% — 25%
Initial (n = 1) (a = II)
delay 4 81.8%
100% = 18.2%
(a = 1) (a = lO) (a = 1)
Strainiag 1 70% 4 lOd%
= 100% = 20%
— 10%
Stream: (a = 2) (a = 7) (a = 1)
— calibreI t 50% 8 71.4% 8 100%
= 50% = 28,6%
—streagth) (a = 4) (n = II) (a = 4)




Seasation of (a = 6) (n = 14) (a = 3)
bladder fullness 4 50%
after micturition = 400% 28.6%
—24.4% —100%
Buraiagon (n = 4) (a 7) (a = 5)
micturition 4 42.8% 4 33.3%
100% 14.4%
— 42.8% — 66.7%
improvement of some symptorns was more noticeable in the
former group, the general tendency was the sarne in both
groups. Initial disturbances tended, for the most part, to
reapear after the end of treatment, although slight improve
rnent was maintained in some cases (Table 3).
Urodynamic values obtained, shown in detail in Fig. 2
to 10 and Table 4, exhibit several statistically significant va
riations caused by both drugs and not by the placebo. The
variation of values on the 8th day under indomethacin was
similar and in certain aspects even more pronounced than at
1 hr. 30 mi. The srnaller number of patients who took
part in the 8th-day group prevents us from drawing any de
finite conclusions.
TABLE 3. Evolution ot symptoma alter the end ol therapy with in
domeibacin and acetylsalicylic acid.
Indomethacin Acetylsalicylic
(n = 23) acid (n = 4)
Diurnal interval “~ 26%
ofmicturitions + 74% + 100%
Number of ‘~ 8.6%
micturitions per
night + 91.4% + 100%





+ 72.7% + 50%
(n=11) (n=2)
Terminal





Straining 28.6% ~o 100%
+ 71.4%
Sensation of (n = 6)
bladder fullness
after micturition + 100%
It should be noted that the variation in parameters for
asymptomatic cases was identical to those which showed cli
nical disturbances. It is important to stress that the correia
tion between clinical and urodynamic data was frequently
poor upon first inspeccion. Some symptoms frequently as
sociated with instability 7 83. ~ (Table 2) were present in pa
tients although the instability itself was not detectable on
the urodynamic curve, even under provocative tests. The
opposite was also true. In two patients, uninhibited contrac
tions were present in the complete absence of symptoms, a
phenomenon noted by other investigators.83 The correlation
between clinical and urodynamic data was much clearer
with regard to micturition fenornena.
TABLE 2. Symptom changes ia 53 patieais sabjected tolhe infiuea
cc aI placebo, iadomethaciii and acetylsalicylic and.
Placebo Iadomethacta Acetylsalicylic








Key: . . . Maintenancc of improvement; + . . . .return to pre-treatment tIa-
te.
key;
....population )aomber of cases); 8 ....iacrease; 4 ....decrease; = sarne
acate; — ....disappearaoce; * ....appearance.
a) «Frequeacy» and uNocturia» are nOt defined since concepta of normal va.
ry widely.
24












































































































A. MATOS FERREIRA AND J. M. REIS SANTOS
The summarized analysis of graphs showing urodyna
mic results using a placebo and indomethacin and aspirin
shows that the prostaglandin synthesis inhibitors brought
about a decline in the slope (Fig. 2) (especially in the tonus
limb), increase in muscular compliance, (Fig. 3) delay in
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Fig. 4 — First desire to void, maximum and effective cystometric
capacities, voided volume and residual urine
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tability disappeared in only a limited number of cases
(21,3% in the indomethacin group). In cases in which insta
bility was still present, after medication, we noted pressure
variations in the contractions which proved to be non signi
ficant when analysed statistically. (Fig. 5).
Greater ease in the onset of micturition, patent in shor
ter opening time, (Fig. 6), and lower intravesical opening
pressure (Fig. 7A,B,C, and D), *as apparent, as was grea
ter ease in the process of micturition as a whole. Maximum
and average flow rates improved, (Fig. 8), with interrupted
streams becoming continuous in some cases (6 in the indo
methacin group and 1 in the aspirin group) (Table 4). One
of the most noteworthy changes was in terminal dribble
which decreased in all cases submitted to medication (Ta
bles 2 and 4). Urethral resistance decreased (Fig. 9) and
pressure flow relationship improved (Fig. 10). In cases whe
re it was present, residual urine decreased (Fig. 4) thus sho
wing improved bladder emptying. Improved flow and vesi
cal emptying were characterized by an overali drop in mie
turition pressures (maximum intravesical pressure and in
travesical pressure at maximum flow) (Fig. 7A,B,C and D).
Post-micturition detrusor contraction suffered non-signifi
cant variations (Fig. 7A,B and C).
Side effects were infrequent with both drugo and their
intensity slight enough to have been considered unimpor
tant by the patients.
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Fig. 9 — Urethral resistance
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DISCUSSION
Two chemically dissimilar drugs — indomethacin and
aspirin — known to be potent prostagiandin synthesis inhi
bitors since Vane’s pioneer study,88 were used in our trial.
Though we admit the possibiity that these NSAID (non-ste
roid anti-inflammatory drugs) can act directly on certain
structures through mechanisms that are stili pooriy unders
tood” ~ ~ 63. 64. 66 it is our opinion that the changes in
bladder and urethrai dynamics we noted, were, at least par
tly due to the synthesis inhibition of prostaglandins which
through complex mechanisms act on specific receptors.52’ 76
The dosage of the drugs, the spacing between administra
tions, and the anaiysis of main urodynamic resuits (1 hr. 30
mm.) were based on pharmacoiogicai knowledge and pre
vious studies using prostagiandin synthesis inhibitors.19 24
Consuitation of other sources13’ ~ 21. 62. 75. 88 ieads us to be
lieve, with little margin of doubt, that the inhibition of
prostagiandin and reiated substances (tromboxanes) was
probabiy complete in ali cases.
Frequent relapse after the end of treatment was taken as
further substantiation of the fact that good results were
probably due to the action mentioned. Inhibitor action is
known to be praticaliy immediate,12’ 52 and since the tissues
do not store prostaglandins to any significant degree, it is
clear that synthesis inhibition represents an inhibition of the
effects.66 89. 90-92 Given this fact, it is likely that inhibitors
such as indomethacin and aspirin, will oniy show any signi
ficant action during the actual period of administration.
We must not disregard the possible effect of the drugs
on central55’ ~ or peripheral sensitivity;9’ 71. 73. ~ and this
might well have been prostaglandin synthesis inhibition as
well.16’ 20, 93 This effect could have had a complementary ac
tion on bladder and urethral structures thus contributing to
the improvement of certain symptoms such as burning upon
micturition, sensation of bladder fuliness after micturition,
deia~ of first sensation with consequent decrease of fre
quency of micturitions, and decrease of biadder sensitivity,
(a possible factor of increased capacity of the organ). We
know however that the pressure at which the micturition re
flex is triggered is the pre-micturition pressure. Since the
micturition reflex appeared when greater bladder capacities
were brought about but under lower pre-micturition pressu
res, it is logical to suppose that local muscular or neuromus
cular action was predominant over a possibie depressive ac
tion on the sensitive sphere.
The analysis of the results in the filling and micturition
phases showed us that both prostaglandin synthetase inhibi
tors brought about diffuse and non-specific muscle relaxa
tion.
Contrary to Ruch’s findings72 the absence of any decline
in the slope for our piacebo group (which, in fact exhibited
some statistically non-significant increase (Fig. 2)), makes it
clear that the distension of the bladder caused by the
pre-medication examination was not a factor in slope decli
ne in patients submitted to the drugs. Bladder hypertonus,
probably due to muscular hypertrophy from pre-operative
obstruction and sometimes patent in high pressures, could
be ascribed, at least to a certain degree, to prostaglandins.
Decrease in bladder hypertonus, caused by the inhibitors,
wouid thus be easy to understand. Slope figures obtained by
us were generally higher than those mentioned by Merril et
ai.6° This was taken as au indicator of hipertonus of purely
muscular origin found in somewhat hipertrophied and da
maged detrusors.72 Detrusor action in the fiiling phase is
know to be non-neural.6’72’8° Thus, it is likely that factors
affecting the detrusor during this phase were of a direct
muscular nature.
We know that several stimuii affect prostaglandins syn
thesis:1822’31’3251’57’58’69’70’74 among them is bladder disten
sion.28’31 Thus, it is altogether possible that prostagiandin
production may be increased in cases like ours. Besides the
mentioned direct muscular action, tissue reaction to neuro
-transmitters may be altered by higher prostaglandin leveis,
which would influence neurovegetative action.36’37’3943
Muscle relaxation caused by the drugs, affected predo
minantly those muscles that make up the intrinsic distal
sphincteric mechanism(Fig. 1). The predominant relaxation
of these muscies(the only functional ones in the posterior
urethra of a prostatectomized patient) would be the oniy
feasible explanation for improved flows and emptying whe
re low intravesical pressures are present.
Decrease in micturition pressures was probabiy due both
to a direct action on the detrusor whose sensivity to prosta
glandin action is experimentally proved,2’5125267 and to the
decrease brought about in urethrai resistance. Is is a known
fact that a decrease in intravesicai pressure, is a normal con
sequence of better urethrai permeablility.
The relaxation of urethrai musculature mentioned,
which is responsible for continence in prostatectomized pa
tients,14 was taken as the cause of heighened sphincteric in
continence.
Cases of ciinicaily and urodynamicaily detected obstruc
tion that improved with treatment were attributed to a pro
bable hypertonic intrinsic striated sphyncter798186 counte
racted by the medication given, which, as experiments ha
ve proved possible, acted directiy on muscular
function.2’5’12’5267 Some improvement may also be ascribed
to more complex and difficult-to-analyse neuro-muscular
mechanisms 12.40.46
Fig. 1 shows the structures on which the protaglandins
had to act in order to cause the changes described. Ghoneim
et ai28 found that the detrusor distension releases PGE2
which, when inhibited by indomethacin, does not exercise
its rela.xing effect on the urethra. Our experience demons
trated a different effect, since we obtained a relaxing effect
on the urethral muscies with thë prostaglandin synthetase
inhibitors. If we keep the multiple and frequently opposing
actions of ali prostaglandins in mmd, it is easy to unders
tand the different results obtained. Analysis of pertinent bi
bliography5’2852’67 only seems to demonstrate the difference
between the results obtained by several investigators. Since
PGF2 contracts the urethral muscles5’53’67 while PGE2 rela
xes them,528’67 it is obvious that the results noted will de
pend on which prostaglandin is acting at any given moment.
The correlation between clinical and urodynamic fac
tors, unclear when first approached, became obvious when
we analysed the improvement of symptoms from the stand
point of the urodynamic changes found. These changes,
though non-specific(appearing identically in asymptomatic
cases and those with clinical disturbances alike), were ob
viously responsible for counteracting those physiopathoio
gical mechanisms behind the clinical dysfunctions we
found.
Instability, a pooriy understood phenomenon,26’83 un
derwent changes detected in our urodynamic study. These
changes though minor, are considered by us to be notewor
thy, given the generaily poor results obtained with even the
most aggressive types of treatment.5664’85 The decrease in
urethral resistance may have had an influence on the impro
vement.83’86 It is important to stress that evento the most as
tute observer, there often seems to be no correlation bet
ween certain symptoms such as frequency, urge incontinen
ce, etc., and urodynamic instability. This occurs not only
upon first approach but also when trial results are analysed.
With the use of indomethacin and aspirin, improvement of
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symptoms was more frequent than improvement of instabi
lity in the urodynamic study.
Some authors7 do not distinguish between long post
-micturition detrusor contractions, which obviously do not
show up in normal urodynamic studies, and those very
short-acting post-micturition contractions, detectable in
these studies. The former type of contraction is a possible
cause of certain symptoms such as sensation of bladder
fullness after micturition. Both types are detrusor contrac
tions3° and possibly signify instability. The causes of these
contractions have been widely interpreted.830’44 In our ca
ses, the short-acting, urodynamically detectable form was
encountered Iess frequently than by other authors827, and
changes resulting from the use of the drugs proved to be
contradictory and inconclusive.
The marked improvement in micturition efficacy easily
expIam the improvement os symptoms such as poor stream,
hesitancy, etc., we obtained in our cases.
Improvement of terminal dribbling, which some investi
gators associated with instability,1 was ascribed to impro
ved emptying of the bladder and a decrease in intravesical
pressure after micturition.
The knowledge we have about the complex action of
prostaglandins on physiological and pathological phenome
na is still very incomplete. This information gap prevents us
at this time from delving deeper into the discussion of preci
se mechanisms involved in the vesico-sphincteric changes
found in our cases.
Up to now, little research has been done into the rela
tionship between prostaglandins and lower urinary tract dy
namics — a field that opens up whole new realm of possibi
lities for the treatment of vesico-sphincteric dysfunctions.
It is our hope that this project, to our knowledge the
first to be done on human subjects in vivo, will provide the
stimulus for further research into this necessary, yet relati
vely unexplored field.
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